Novo Nordisk launches 'Power of Wegovy' national campaign
![](/46/pdcnewsitem/12/46/00/Heading%20image%20(8).png)
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States.
Novo Nordisk, the pharmaceutical giant behind drug products Wegovy and Ozempic, have announced the launch of their campaign ‘The Power of Wegovy’ in an effort to educate on the clinical data of Wegovy 2.4 mg injection.
Wegovy is Novo Nordisk’s blockbuster injectable for the treatment of obesity and weight-related medical complications. Originally sold as Ozempic for the treatment of diabetes, Wegovy is a semaglutide injection for chronic weight management and reduced the risk of stroke, heart attack, and/or death in overweight or obese patients when used in tandem with low-calorie diets and exercise. Semaglutide injections like Wegovy and Ozempic mimic the GLP-1 hormone released in response to eating by the gastrointestinal (GI) tract. This helps the body produce more insulin and reduces blood glucose. In higher amounts, GLP-1 can reduce appetite and create feelings of fullness.
The Power of Wegovy campaign will focus on reinforcing the FDA’s approval of Wegovy among obese and overweight patients as well as the general public. The campaign follows an update to the approval of Wegovy by the FDA, which removed body mass index (BMI) descriptors from weight-management indications and introduced new cardiovascular risk reduction indications. “Diverse representation in health care campaigns can play a significant role in patients feeling seen, heard, and understood, especially in stigamtized space like obesity, which we’ve been engaged in for more than 2 decades,” commented Tejal Vishalpura, Senior Vice President, Commercial Strategy and Marketing at Novo Nordisk. “The Power of Wegovy is committed to representing a cross-section of unique perspectives at this cultural inflection point in society, especially when the connection between obesity, cardiovascular risk, and the importance of patient-centred care is so much a part of the public discourse.”
The Power of Wegovy campaign hopes to provide diverse and unique portrayals of individuals who have partnered with their healthcare professionals throughout their weight-management journey, while providing information and educating on the clinical data for Wegovy. With these personal stories, Novo Nordisk aims to address stigma in weight management and obesity treatments.
Source:
Novo Nordisk launches national Wegovy campaign, Power of Wegovy [Accessed June 5, 2024] https://www.prnewswire.com/news-releases/novo-nordisk-launches-national-wegovy-campaign-power-of-wegovy-302162020.html
Related News
-
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News Sanofi to collaborate with OpenAI and Formation Bio
Pharmaceutical giant Sanofi have announced a collaboration with Formation Bio and OpenAI to build AI-powered software for accelerated drug development. -
News AstraZeneca to build billion-dollar ADC manufacturing site in Singapore
The British-Swedish drugmaker has announced plans to build a US$1.5 billion facility in Singapore for the manufacturing of antibody–drug conjugates (ADCs) to complement their existing cancer drug portfolio. -
News Women in Pharma: Delivering personal and professional success
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Eisai begins US FDA rolling submission for Alzheimer’s drug Leqembi
Japanese drugmaker Eisai, in partnership with Biogen, have announced that they have begun submitting data on a rolling basis to the US FDA for a marketing application of a subcutaneous injectable form of Alzheimer’s drug Leqembi. -
News Racial disparities in diagnosis and drug use for dementia symptoms
A study from the USC Schaeffer Center for Health Policy & Economics has revealed the existence of racial disparities in the US for the diagnosis of dementia and the use of drug treatments for symptoms. -
News MDMA-assisted therapy for PTSD to be reviewed by US FDA
American public benefit corporation (PBC) Lykos Therapeutics have announced that the US FDA Psychopharmacologic Drugs Advisory Committee (PDAC) will review data supporting their new drug application (NDA) for MDMA capsules, which are to be used in comb...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance